Searchable abstracts of presentations at key conferences in endocrinology

ea0026p246 | Pituitary | ECE2011

AcroBel-2: the Belgian follow-up survey on acromegaly: contribution of pituitary surgery and the use of pegvisomant to an improvement in disease control

Bex M , Abs R , T'Sjoen G , Corvilain B , Velkeniers B , Maiter D

Two nationwide surveys on acromegaly (AcroBel-1 and 2) have been performed in Belgium at an interval of five years, including centralized GH and IGF1 measurements in most patients. A normal IGF1 for age was observed in 56% of 311 vs 74% of 365 treated patients, in 2004 and 2009 respectively.Factors responsible for this improvement were investigated. A selection bias was unlikely as the follow-up rate was higher in patients with active (83%) or medically ...

ea0011p510 | Endocrine tumours and neoplasia | ECE2006

AcroBel: a registry and survey on acromegaly in Belgium

Bex M , Abs R , T’Sjoen G , Mockel J , Velkeniers B , Maiter D

To evaluate the epidemiology and global quality of care of acromegaly in Belgium, all endocrinologists treating patients with acromegaly were invited to participate in a nationwide survey extending from 15-6-2003 till 30-9-2004, aiming to include all patients (including deaths) that were in follow up or newly diagnosed after 1-1-2000. The project was ethically approved and written informed consent obtained. Retrospective data on demographics, pathology, complications and treat...

ea0002p68 | Neuroendocrinology | SFE2001

SAFETY AND MORTALITY DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN 4457 ADULT GH-DEFICIENT PATIENTS - A KIMS DATABASE ANALYSIS

Monson J , Abs R , #B-A|#Bengstonn|# , Feldt-Rasmussen U , Goth M , Koltowska M , Mattsson A , Westberg B , Wilton P

This analysis is based on 4457 patients (2365 males, 2092 females; mean age 44 years, range 18-83) with severe GH deficiency (GHD) enrolled in KIMS (pharmaco-epidemiological survey of GH replacement in adult GH-deficient patients, sponsored by Pharmacia Corporation). The mean duration of adult GH replacement was 2.8 years (range 0.1-11.0) giving 10,779 patient years of follow up. The baseline prevalence of diabetes mellitus prior to GH replacement was 3.7 % (compared with popu...